Drugs generally stay in a newborn’s system far longer than they would in an adult, often two to several times longer depending on the substance, because a baby’s liver and kidneys are not yet equipped to break down and eliminate chemicals efficiently. The exact duration depends on which drug, how the baby was exposed, the baby’s gestational age, and individual physiology. Understanding the timelines requires looking at how newborns handle drugs differently from adults, what kinds of exposure matter most, and how hospitals detect and monitor these substances.
Why a Newborn’s Body Is Slow to Clear Drugs
The liver is the body’s main drug-processing factory, and in newborns it is still under construction. The enzymes responsible for breaking down medications develop on different schedules. Some switch on within hours of birth, while others take weeks or months to reach full activity.1Toxicology. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children One important group of enzymes involved in deactivating many common drugs does not fully mature until roughly six months to a year of age.2PubMed Central. The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver Until those enzymes are running at full capacity, a drug that an adult might clear in a few hours can linger in a baby’s bloodstream for days.
The kidneys add another bottleneck. A newborn’s kidneys filter blood at a fraction of the adult rate and continue maturing over the first two years of life. This reduced kidney function slows down the elimination of drugs that are normally flushed out through urine.3PubMed Central. Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children On top of that, both metabolic and renal clearance pathways are immature at birth, which can lead to a prolonged half-life for many medications.4PubMed Central. Developmental pharmacokinetics in pediatric populations
Body composition plays a role too. Newborns have proportionally more water and less fat than adults, and their blood proteins bind drugs less tightly. These differences change how drugs spread through the body and how quickly they reach the organs that process them.5PubMed Central. Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults For a water-soluble drug, the larger water compartment dilutes the dose more, but for a fat-soluble drug, there is less tissue to absorb it, meaning it stays in circulation longer. The net effect depends on the specific drug, but the overall pattern is the same: drugs hang around in a baby’s system longer than you would expect based on adult data.
Opioids and In Utero Substance Exposure
When a pregnant person uses opioids regularly, the drug crosses the placenta and the baby becomes physically dependent before birth. After delivery, the baby goes through withdrawal, a condition called neonatal abstinence syndrome. The severity and duration of that withdrawal reflects how long the drug and its effects persist in the newborn’s body.
Not all opioids are equal in this regard. In a randomized trial comparing methadone and buprenorphine, babies exposed to buprenorphine needed treatment for withdrawal for about four days on average, while babies exposed to methadone required roughly ten days. Hospital stays told a similar story: about ten days for the buprenorphine group versus more than seventeen days for the methadone group.6PubMed Central. Neonatal abstinence syndrome after methadone or buprenorphine exposure A separate retrospective study confirmed the pattern, finding that babies exposed to buprenorphine needed about six fewer days of morphine treatment than those exposed to methadone.7PubMed Central. Differences in hospital length of stay between neonates exposed to buprenorphine versus methadone in utero These timelines reflect how long the baby’s system takes to adjust after losing a steady supply of the drug, and they give families a rough sense of what to expect in the days and weeks after birth.
Cannabis presents a different picture. THC, the psychoactive component, is fat-soluble and readily crosses the placenta, though the fetus appears to receive lower concentrations than the mother.8PubMed Central. Cannabis use during pregnancy: Pharmacokinetics and effects on child development Because THC accumulates in fatty tissue, it can persist in the body for weeks. In a newborn with less body fat, clearance dynamics differ from an adult’s, but the drug’s fat-loving nature still means it does not wash out quickly. Cannabis does not typically cause a dramatic withdrawal syndrome the way opioids do, but its metabolites can be detected in a baby’s system for a surprisingly long window after birth, as discussed in the testing section below.
Medications Given During Labor and Delivery
Drugs used during childbirth can cross to the baby in the final hours before birth, and the newborn then has to clear those drugs with an immature system. A classic example comes from older research on pethidine (also known as meperidine), a painkiller once commonly used in labor. In newborns, bupivacaine, a local anesthetic used in epidurals, was largely cleared within about a day. Pethidine, however, took between two and six days for the baby to eliminate. Researchers noted that this slow clearance could explain the lingering drowsiness and breathing depression sometimes seen in babies whose mothers had received pethidine during labor.9PubMed Central. Elimination of pethidine and bupivacaine in the newborn
That example illustrates a broader point: even drugs considered safe for the mother can behave unpredictably in the baby. The same local anesthetic family used in epidurals shows wide variation in how quickly individual infants clear it, with some babies processing it much more slowly than others.10PubMed. Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age This variability is why obstetric anesthesiologists carefully choose which agents to use and at what doses, particularly when delivery is imminent and the drug will have limited time to clear the mother’s system before reaching the baby.
Drugs Transferred Through Breast Milk
Breastfeeding is another route by which drugs enter a baby’s system, though the amounts involved are usually much smaller than what crosses the placenta. How much drug a nursing infant actually absorbs depends on two things working together: how concentrated the drug is in milk compared with the mother’s blood, and how quickly the mother’s own body clears the drug. These two factors can produce counterintuitive results. Phenobarbital, for instance, has a relatively low concentration in milk compared with blood, yet the baby can still receive a substantial dose because the drug clears slowly from the mother, keeping levels high around the clock. Morphine, on the other hand, concentrates in milk at double the blood level but clears quickly from the mother’s body, so the baby’s overall exposure ends up being modest.11PubMed. Infant drug exposure via breast milk
For antidepressants, which many new parents worry about, most newer medications produce very low or undetectable levels in the nursing infant’s blood. The exceptions where slightly higher infant levels have been reported include fluoxetine, citalopram, and venlafaxine, and suspected side effects in the baby have occasionally been noted with fluoxetine and citalopram specifically.12PubMed Central. Antidepressant Use During Breastfeeding Still, once the drug is in the baby, it faces the same immature metabolism described earlier, so even a small dose can have a proportionally larger effect than it would in an adult. This is why healthcare providers weigh the benefits of breastfeeding and maternal mental health treatment against the small but real possibility that the drug will linger in the infant’s system.
How Hospitals Test Newborns for Drug Exposure
Understanding how long drugs stay in a baby’s system also matters for detection. Hospitals use several types of specimens to screen newborns, and each one captures a different window of exposure.
Urine is the most commonly collected sample, but it captures the narrowest timeframe, reflecting drug use only in the few days before delivery.13Clinics in Laboratory Medicine. Drug Testing in the Neonate – Section: Specimens from the Neonate This means a mother who used a substance early in pregnancy but stopped well before birth might not test positive on a neonatal urine screen. It also means that timing matters: if the urine is collected too late or too early, results may be misleading.
Meconium, the dark stool a baby passes in the first day or two of life, offers a much longer detection window. Because meconium begins forming around the twelfth week of pregnancy and accumulates substances over the remainder of gestation, it can reveal exposure from the second and third trimesters. One study found meconium was marginally more sensitive than neonatal hair for detecting cocaine and cannabis, likely because meconium captures second-trimester exposure while hair only grows during the third trimester.14PubMed Central. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse
Umbilical cord tissue has gained popularity as a testing specimen because it is available immediately at birth and does not require waiting for the baby to produce a stool or urine sample. One early comparison showed agreement above 90% between cord tissue and meconium for most drug classes, including opiates, cocaine, and amphetamines.15PubMed. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium However, more recent work has complicated the picture. A retrospective study of over 500 neonates found that drug detection results between cord tissue and meconium were often discordant, meaning one sample might flag a drug that the other missed.16PubMed Central. Umbilical Cord Tissue and Meconium May Not Be Equivalent for Confirming in Utero Substance Exposure Another study shed some light on why: drug concentrations tend to be higher in meconium for most compounds, but positivity rates were higher in cord tissue for most analytes, suggesting that cord tissue testing may be more analytically sensitive under current methods.17PubMed Central. Can Umbilical Cord and Meconium Results Be Directly Compared? Analytical Approach Matters
The practical takeaway is that no single test specimen is perfect. Urine catches only the very recent past. Meconium captures a broader window but requires waiting for the baby to pass stool, which can take a day or more. Cord tissue is convenient and quick but may not agree with meconium results for every substance. Hospitals increasingly use more than one specimen type when exposure is suspected, precisely because these tests complement each other rather than being interchangeable.
Premature Babies Face Even Longer Clearance Times
Everything discussed so far applies to full-term newborns, who are already at a disadvantage compared with adults. Premature babies have even less developed organs, and their ability to metabolize drugs is further reduced. A scoping review of drug metabolism studies in preterm infants noted that the research is frustratingly sparse: more than 40% of the studies examined did not clearly distinguish between term and preterm results, making it difficult to draw firm conclusions about how quickly premature infants clear specific drugs.18PubMed Central. The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children What is known, though, is that the enzyme systems responsible for drug breakdown are even less mature in preterm infants, meaning clearance times can be substantially longer. This is one reason neonatal intensive care units are so cautious with dosing, often using weight-based calculations that account for gestational age.
Sick newborns who undergo therapeutic hypothermia, a treatment where the baby’s body temperature is deliberately lowered to protect the brain after oxygen deprivation, face another complication. Cooling slows down the liver’s enzyme activity even further, meaning drugs administered during hypothermia stick around longer than they would at normal body temperature.19PubMed Central. Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review Clinicians managing these babies have to adjust doses downward and extend the intervals between doses to avoid drug accumulation.
When Babies Receive Medications Directly
Beyond passive exposure from the mother, babies sometimes need medications for their own medical conditions. Acetaminophen (paracetamol) is one of the most commonly given drugs in infancy, used for pain and fever. While studies have confirmed that it does not cause acute liver damage in babies when used as directed, the long-term picture is less clear. A systematic review tracking the safety evidence found that no clinical trial had actually monitored neurodevelopment as an outcome, and none had accounted for a baby’s total lifetime exposure to the drug.20PubMed Central. Paracetamol (acetaminophen) use in infants and children was never shown to be safe for neurodevelopment: a systematic review with citation tracking That gap in the evidence does not mean acetaminophen is harmful, but it does mean the reassurance many parents feel about it is based on short-term liver safety data rather than comprehensive long-term studies.
For any medication given directly to an infant, the clearance question is critical because dosing errors are more consequential. An adult with mature liver and kidney function has a larger margin for error; a newborn does not. The same immature enzyme systems and sluggish kidney filtration that slow down clearance of drugs passed from the mother also slow down clearance of medications the baby takes directly. This is why pediatric drug dosing is so carefully calibrated and why medications are sometimes given less frequently to young infants than to older children or adults.
Rough Timelines by Drug Class
Giving a single number for “how long drugs stay in a baby’s system” is genuinely difficult because the answer depends on the specific drug, the baby’s age and maturity, and the route of exposure. But some general patterns emerge from the research:
- Opioids (in utero): Withdrawal symptoms from methadone exposure can require treatment for about ten days on average, with hospital stays stretching beyond two weeks. Buprenorphine withdrawal tends to resolve in roughly half that time.
- Labor painkillers: Local anesthetics like bupivacaine are typically cleared within a day. Pethidine, by contrast, can take two to six days for a newborn to eliminate.
- Cannabis: THC metabolites can be detected in meconium samples reflecting exposure from the second trimester onward, and the drug’s fat-soluble nature means traces may persist for weeks in body tissues.
- Antidepressants (via breast milk): Most produce very low or undetectable levels in the baby’s blood, though fluoxetine and citalopram can reach measurable concentrations. The baby’s slow metabolism means even low levels may persist longer than they would in an adult.
- Acetaminophen: Short-term clearance is generally adequate in healthy full-term infants, though the immature enzyme systems mean the half-life is longer than in older children.
These are broad strokes. Individual variation is significant, especially between premature and full-term infants, and between healthy newborns and those with medical complications. Any concern about a specific drug should be discussed with a pediatrician or neonatologist who can factor in the baby’s particular circumstances.
Why the Research Is Thinner Than You Might Expect
One of the more surprising aspects of this topic is how much remains unknown. Studying drug clearance in newborns is ethically constrained because you obviously cannot run the same kinds of dosing experiments in babies that you can in adult volunteers. Much of what we know comes from observational data, opportunistic blood sampling when babies need blood draws for other reasons, and extrapolation from animal models. The scoping review on premature infants highlighted that researchers often lump term and preterm babies together in their analyses, making it hard to tease apart the specific timelines for the most vulnerable population.18PubMed Central. The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children Similarly, the drug testing literature shows ongoing debate about which specimen types are most reliable, with studies producing conflicting results depending on methodology and the specific substances being tested.17PubMed Central. Can Umbilical Cord and Meconium Results Be Directly Compared? Analytical Approach Matters
This uncertainty is not a reason for panic. It is context for understanding why your pediatrician may give you a range rather than a precise number when you ask how long a drug will affect your baby. The science of neonatal pharmacology is advancing, with better modeling tools and more targeted studies, but for now, conservative dosing and close monitoring remain the standard approach. When in doubt, the safest assumption is that any drug will take longer to leave a baby’s system than it would yours, and potentially much longer if the baby was born early or is medically fragile.